Live feed07:00:00·59dPRReleasevia QuantisnowHarrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery IndicationByQuantisnow·Wall Street's wire, on your screen.HROW· Harrow Inc.Health Care
